© 2005 Foundation for Promotion of Cancer Research
Multipoint Oncology Teleconference, Japan |
Multipoint Oncology Teleconference, Japan
This teleconference has been held on a weekly basis (on Thursday evenings) as a good opportunity for the discussion of important issues in clinical oncology. Nowadays, this plenary meeting among the major cancer centers is indispensable for maintaining the high standard of quality of cancer clinics throughout Japan.
Review (May, 2005 series)
May 12: Treatment of follicular lymphoma (moderated by Dr Morishima, Aichi Cancer Center, Nagoya). Recently, the treatment outcome of patients with follicular lymphoma has been greatly improved by the advent of several new strategies. Issues surrounding the treatment of choice were extensively discussed. Dr Ogura (Aichi Cancer Center) showed improved outcome in the treatment of follicular lymphoma by the introduction of anti-CD20 antibody, purine analogue, and radioimmunotherapy. Dr Kagami (Aichi Cancer Center) presented the transplantation of CD34-positive cells in combination with rituximab in vivo purging for advanced follicular lymphoma, in order to reduce the risk of recurrence. Dr Taji (Aichi Cancer Center) reported eight cases of auto-BMT for recurrent follicular lymphoma. Dr Tobinai (NCC) reported the present status and future perspectives of 90Y-labelled CD20 antibody treatment, and other promising new agents for the treatment of follicular lymphoma.
May 19: Dendric cell immunotherapy (moderated by Dr Minami, Shikoku Cancer Center, Matsuyama). Among the various new vaccine treatments, no agent has ever been used in practice. The Shikoku Cancer Center developed a RNA/dendric cell (DC) treatment and analyzed its biological functions. Dr Takayama (Tokyo University) reported on the result of a phase I study of local injection of radiated DC for advanced cancer. Although no serious adverse effect was noted, the anti-tumor effect was not clearly observed. Dr Akiyama (Shizuoka Cancer Center) also reported on the result of a phase I study of DC treatment using antigen-peptide for metastatic melanoma. As the tumor response, CR was seen in one, PR in one, SD in one, and PD in three patients. Dr Minami (Shikoku Cancer Center) developed an antigen presenting cell (APC) treatment by introducing mRNA, extracted from tumor cells, into DC. This APC was shown to be a useful tool to induce effector cells in adoptive immunotherapy.
For Japanese readers, detailed information of the conferences, including videos and slides of the presentations are available at http://www.ncc.go.jp/jp/ncc-cis/pro/vod/index.html.
Institutions networked by a multipoint teleconference system: National Hospital Organization Hokkaido Cancer Center, Aomori Prefectural Central Hospital, Iwate Prefectural Central Hospital, Miyagi Cancer Center, Yamagata Prefectural Central Hospital, Ibaraki Prefectural Central Hospital, Niigata Cancer Center, Gunma Prefectural Cancer Center, National Cancer Center, East, National Cancer Center, Chiba Cancer Center, Saitama Cancer Center, Shizuoka Cancer Center, Aichi Cancer Center, Osaka Medical Center for Cancer and Cardiovascular Diseases, National Hospital Organization Kure Medical Center, National Hospital Organization Shikoku Cancer Center, National Hospital Organization Kyusyu Cancer Center.
|
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||